Screener
BioCryst Pharmaceuticals BCRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031238
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of debt issuance costs on term loan | (4,952) | — |
| Principal payments on royalty financing obligations | (476) | — |
| Principal payments on finance lease liabilities | (345) | (516) |
| Net cash provided by financing activities | 412,552 | 529 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | (72) | 451 |
| Net increase in cash, and cash equivalents, and restricted cash | 82,041 | 558 |
| Cash, cash equivalents and restricted cash: | ||
| Beginning of period | 91,337 | 106,323 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's financing cash flow?
- BioCryst Pharmaceuticals (BCRX) reported financing cash flow of $412.55M in Q1 2026.
- How has BioCryst Pharmaceuticals's financing cash flow changed year-over-year?
- BioCryst Pharmaceuticals's financing cash flow increased by 77887.1% year-over-year, from $529K to $412.55M.
- What is the long-term trend for BioCryst Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's financing cash flow has grown at a -0.9% compound annual growth rate (CAGR), from $359.67M to -$349.93M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about BioCryst Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude